

AVEO PHARMACEUTICALS INC
Form SC 13G/A
February 14, 2014
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

AVEO Pharmaceuticals Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

053588109

(CUSIP Number)

December 31, 2013

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

£Rule 13d-1(b)

SRule 13d-1(c)

£Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

NAMES OF REPORTING PERSONS

Great Point Partners, LLC

1.

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

37-1475292

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2. (a) £

(b) £

3. SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

4.

USA

SOLE VOTING POWER

5.

NUMBER OF SHARES 0

BENEFICIALLY SHARED VOTING POWER

OWNED BY EACH 6.

REPORTING PERSON 3,000,000

WITH 7.SOLE DISPOSITIVE POWER

0

SHARED DISPOSITIVE POWER

8.

3,000,000

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9.

3,000,000

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.

5.78%¹

TYPE OF REPORTING PERSON (See Instructions)

12.

IA

¹ Based on a total of 51,862,392 shares of Common Stock outstanding, as reported in the Issuer's Form 10-Q filed with the SEC on November 7, 2013.

NAMES OF REPORTING PERSONS

1. Dr. Jeffrey R. Jay, M.D.

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) £

2.

(b) £

3. SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

4.

USA

NUMBER OF SHARES SOLE VOTING POWER

BENEFICIALLY 5.

OWNED BY EACH 0

REPORTING PERSON SHARED VOTING POWER

WITH 6.

3,000,000

SOLE DISPOSITIVE POWER

7.

0

8.SHARED DISPOSITIVE POWER

3,000,000

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9.

3,000,000

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) £

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.

5.78%¹

TYPE OF REPORTING PERSON (See Instructions)

12.

IN

NAMES OF REPORTING PERSONS

1. Mr. David Kroin

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) £

2.

(b) £

3. SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

4.

USA

NUMBER OF SHARES SOLE VOTING POWER

BENEFICIALLY 5.

OWNED BY EACH 0

REPORTING PERSON SHARED VOTING POWER

WITH 6.

3,000,000

SOLE DISPOSITIVE POWER

7.

0

8.SHARED DISPOSITIVE POWER

3,000,000

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9.

3,000,000

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) £

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.

5.78%¹

TYPE OF REPORTING PERSON (See Instructions)

12.

IN

CUSIP No. 053588109 **13G/A** Page 5 of 9 Pages

Item 1.

(a) Name of Issuer

AVEO Pharmaceuticals Inc.

(b) Address of Issuer's Principal Executive Offices

650 E. Kendall Street, Cambridge MA 02142

Item 2.

(a) Name of Person
Filing

Great Point
Partners, LLC
Dr. Jeffrey R.
Jay, M.D.
Mr. David
Kroin

The Reporting
Persons have
entered into a Joint
Filing Agreement,
dated February 14,
2014, a copy of
which is filed with
this Schedule
13G/A as Exhibit
A, pursuant to
which the
Reporting Persons
have agreed to file
this statement
jointly in
accordance with
the provisions of
Rule 13d-1(k)(1)
under the Act.

Address of
Principal
(b) Business Office,
or if none,
Residence

The address of
the principal
business office
of each of the
Reporting
Persons is

165 Mason
Street, 3rd Floor
Greenwich, CT
06830

(c) Citizenship

Great Point
Partners, LLC is a
limited liability
company organized
under the laws of
the State of
Delaware. Dr.
Jeffrey R. Jay,
M.D. is a citizen of
the United States.
Mr. David Kroin is
a citizen of the
United States.

(d) Title of Class of
Securities

Common Stock

(e) CUSIP Number

053588109

**If this statement is
filed pursuant to
§240.13d-1(b) or
Item 3. 240.13d.2(b) or
(c), check whether
the person filing is
a:**

Not Applicable.

(a) £ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)

(b) £ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)£ Insurance company as defined in Section 3(a)(19) of the Act (15. U.S.C. 78c).

(d)£ Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e)£ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

- (f) £ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
- (g) £ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
- (h) £ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
- (i) £ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
- (j) £ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4. Ownership

Biomedical Value Fund, L.P. (“BVF”) is the record owner of 1,530,000 shares of Common Stock (the “BVF Shares”). Great Point Partners, LLC (“Great Point”) is the investment manager of BVF, and by virtue of such status may be deemed to be the beneficial owner of the BVF Shares. Each of Dr. Jeffrey R. Jay, M.D. (“Dr. Jay”), as senior managing member of Great Point, and Mr. David Kroin (“Mr. Kroin”), as special managing member of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares.

Biomedical Offshore Value Fund, Ltd. (“BOVF”) is the record owner of 900,000 shares of Common Stock (the “BOVF Shares”). Great Point is the investment manager of BOVF, and by virtue of such status may be deemed to be the beneficial owner of the BOVF Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares.

Biomedical Institutional Value Fund, L.P. (“BIVF”) is the record owner 570,00 shares of Common Stock (the “BIVF Shares”). Great Point is the investment manager of BIVF, and by virtue of such status may be deemed to be the beneficial owner of the BIVF Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the BIVF Shares, and therefore may be deemed to be the beneficial owner of the BIVF Shares.

Notwithstanding the above, Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of the BVF Shares, the BOVF Shares, and the BIVF Shares, except to the extent of their respective pecuniary interests.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

1. **Great Point Partners, LLC**

- (a) Amount beneficially owned: 3,000,000
- (b) Percent of class: 5.78%²
- (c) Number of shares as to which the person has:

²Based on a total of 51,862,392 shares of Common Stock outstanding, as reported in the Issuer's Form 10-Q filed with the SEC on November 7, 2013.

CUSIP No. 053588109 **13G/A** Page 7 of 9 Pages

- (i) Sole power to vote or to direct the vote: - 0 -
- (ii) Shared power to vote or to direct the vote: 3,000,000
- (iii) Sole power to dispose or to direct the disposition of: - 0 -.
- (iv) Shared power to dispose or to direct the disposition of: 3,000,000

2. Dr. Jeffrey R. Jay, M.D.

- (a) Amount beneficially owned: 3,000,000
- (b) Percent of class: 5.78%²
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote: 0.
 - (ii) Shared power to vote or to direct the vote: 3,000,000
 - (iii) Sole power to dispose or to direct the disposition of: 0.
 - (iv) Shared power to dispose or to direct the disposition of: 3,000,000

3. Mr. David Kroin

- (a) Amount beneficially owned: 3,000,000
- (b) Percent of class: 5.78%²
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote: 0.
 - (ii) Shared power to vote or to direct the vote: 3,000,000
 - (iii) Sole power to dispose or to direct the disposition of: 0.
 - (iv) Shared power to dispose or to direct the disposition of: 3,000,000

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

**Item 6. Ownership of
More than
Five Percent
on Behalf of
Another
Person:**

See Item 4.

**Item 7. Identification
and
Classification
of the
Subsidiary
Which
Acquired the
Security
Being
Reported on
by the Parent
Holding
Company**

Not
Applicable.

**Item 8. Identification
and
Classification
of Members
of the Group**

Not
Applicable.

CUSIP No. 053588109 **13G/A** Page 8 of 9 Pages

**Notice of
Item 9. Dissolution
of Group**

Not
Applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect.

CUSIP No. 053588109 **13G/A** Page 9 of 9 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2014

GREAT POINT PARTNERS,
LLC

By: /s/ Dr. Jeffrey R. Jay, M.D.
Dr. Jeffrey R. Jay, M.D.,
as senior managing member

/s/ Dr.
Jeffrey R.
Jay, M.D.
DR.
JEFFREY
R. JAY,
M.D.

/s/ Mr.
David
Kroin
MR.
DAVID
KROIN

Exhibit A

AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G/A

The undersigned hereby agree as follows:

(i) Each of them is individually eligible to use the Schedule 13G/A to which this Exhibit is attached, and such Schedule 13G/A is filed on behalf of each of them; and

(ii) Each of them is responsible for the timely filing of such Schedule 13G/A and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Date: February 14, 2014

GREAT POINT PARTNERS,
LLC

By: /s/ Dr. Jeffrey R. Jay, M.D.
Dr. Jeffrey R. Jay, M.D.,
as senior managing member

/s/ Dr.
Jeffrey R.
Jay, M.D.
DR.
JEFFREY
R. JAY,
M.D.

/s/ Mr.
David
Kroin
MR.
DAVID
KROIN